Lisata Therapeutics, Inc. — Form 10-Q Summary
Period note: The request metadata says 2023 Q1, but the filing itself is for the three months ended March 31, 2024, with comparisons to Q1 2023. This summary follows the filing period.
Business context and reporting period
Lisata is a clinical-stage pharmaceutical company developing certepetide (LSTA1), an investigational therapy intended to improve delivery of cancer treatments into solid tumors. The company reported several ongoing global Phase 2 studies across tumor types. It had no revenue in either Q1 2024 or Q1 2023.
Key financial metrics
| Metric | Q1 2024 / March 31, 2024 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $0 | $0 in Q1 2023 |
| Research and development expense | $3.241 million | $3.179 million in Q1 2023 |
| General and administrative expense | $3.360 million | $3.665 million in Q1 2023 |
| Total operating expenses / operating loss | $6.601 million | $6.844 million in Q1 2023 |
| Net loss | $5.401 million | $6.187 million in Q1 2023 |
| Basic and diluted loss per share | $0.65 | $0.77 in Q1 2023 |
| Cash and cash equivalents | $21.805 million | $22.593 million at December 31, 2023 |
| Marketable securities | $21.544 million | $27.942 million at December 31, 2023 |
| Cash, cash equivalents and marketable securities | $43.349 million | $50.535 million at December 31, 2023 |
| Net cash used in operating activities | $7.027 million | $8.196 million in Q1 2023 |
| Working capital / stockholders’ equity | $42.2 million / $43.0 million | At March 31, 2024 |
| Total liabilities | $5.497 million | $6.800 million at December 31, 2023 |
The filing reports no debt balance. No gross margin is meaningful because the company recorded no revenue.
Material changes versus Q1 2023 and year-end
- Net loss narrowed by $786,000, while operating expenses decreased by $243,000. Lower G&A costs—partly from reduced staffing, insurance, consulting and legal spending—more than offset a modest increase in R&D spending.
- R&D expense rose $62,000, mainly reflecting enrollment in the Bolster Phase 2a study, partly offset by lower costs after completion of enrollment in the ASCEND Phase 2b study.
- The Q1 2024 net loss included a $798,000 income tax benefit associated with selling New Jersey net operating losses. The sale generated $700,000 in net proceeds; a $100,000 loss on sale was recorded in other expense.
- Cash and marketable securities declined by approximately $7.2 million from year-end. The company used $7.0 million in operating cash; investing cash inflow primarily reflected net sales of marketable securities.
Outlook, risks, contingencies and unusual items
- Management expects existing cash and marketable securities to fund operating expenses for at least 12 months following issuance of the financial statements. Future funding needs depend on clinical development and strategic arrangements.
- Lisata cautions that additional financing may not be available on acceptable terms. Potential equity financing could dilute shareholders; debt, if available, could impose payment obligations and restrictive covenants. The company also cites clinical, regulatory, enrollment, intellectual-property and partnership risks.
- The ATM program had no share sales in Q1 2024. Due to the Form S-3 “Baby Shelf” limitation, the company disclosed approximately $8.9 million as the amount it was then permitted to offer and sell.
- A March 2024 settlement of Lingmed litigation required a $500,000 payment, made April 4, 2024. Lingmed is also entitled to 5% of future milestones under the Qilu license and an additional $250,000 upon the first future milestone. The case was dismissed with prejudice in April.
- On March 15, 2024, Lisata invested $100,000 in an Impilo Therapeutics SAFE; the investment was expensed under the equity method in Q1.
- Management stated disclosure controls were effective at a reasonable-assurance level and reported no material changes to internal control over financial reporting. A new principal financial and accounting officer was appointed effective April 15, 2024.
Important facts for investors to verify
- Confirm the intended reporting period: the supplied metadata says Q1 2023, while the filing covers Q1 2024.
- Review clinical-trial progress, enrollment timing and forthcoming data for certepetide, including the Bolster and ASCEND programs.
- Track cash burn and the company’s ability to sustain operations beyond management’s stated 12-month runway, including any subsequent financing or ATM sales.
- Check the timing and terms of potential Qilu milestones, royalties and sublicensing payments, including Lingmed’s settlement participation.
- Assess the effect of the Baby Shelf limitation and potential dilution from future equity issuance.